This is the first comprehensive text to provide not only a detailed explanation of how the SARS-CoV2 (COVID-19) virus is spread within human populations, but also an epidemiological analysis and interpretation of viral pandemics to enable better measures for prevention and control. Providing an introduction to the physiology of both the human immune system and the SARS-CoV2 virus, specifically the virus's replicative potential and our own vulnerability, the book offers an in-depth understanding of how the pandemic evolved. It also highlights the aberrant epigenomic mechanistic process in…mehr
This is the first comprehensive text to provide not only a detailed explanation of how the SARS-CoV2 (COVID-19) virus is spread within human populations, but also an epidemiological analysis and interpretation of viral pandemics to enable better measures for prevention and control. Providing an introduction to the physiology of both the human immune system and the SARS-CoV2 virus, specifically the virus's replicative potential and our own vulnerability, the book offers an in-depth understanding of how the pandemic evolved. It also highlights the aberrant epigenomic mechanistic process in pathogenic microbe's replication and survival, implying gene and environment interaction that affected different populations. Citing a range of environmental conditions, from structural and systemic racism to malnutrition and low-socioeconomic status, the book examines how these factors exacerbated existing health disparities, resulting in a disproportionate burden of morbidity and mortality on certain social groups. Also providing invaluable guidance on how future iterations of this pandemic may be better prevented and controlled, this will be a defining book for students, researchers and professionals within Public Health and Clinical Medicine to better understand the SARS-CoV2 (COVID-19) virus, and how to protect the most vulnerable social groups.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Laurens (Larry) Holmes, Jr. is an immunologist and infectious disease specialist, and obtained his doctoral degree in cancer epidemiology and biostatistics from the University of Texas, Health Sciences Center at Houston. He is a Principal Translational Research Scientist, a former Founding Director of the Nemours Paediatric Translational Health Disparities Science research, training and education program, Wilmington, DE (USA), a leading proponent of epigenomic epidemiology in clinical medicine and public health and Affiliate professor of molecular epidemiology and clinical trials at the Biological Sciences Department at the University of Delaware, Newark, DE (USA), Co-founder and Director of Global Health Equity Foundation (GHEF-USA) and Founding Director of Lawhols International Scientific Research Consulting, LIS-RC (USA). Professor Holmes is currently a Director of the Graduate Public Health Program (Epidemiology and Global Health), Public Health & Allied Health Sciences Department, Wesley College-Delaware State University, Dover, DE (USA).
Inhaltsangabe
1.Immuno epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS CoV2 (COVID 19): Pandemic and Public Health Emergency Response. 4.SARS CoV2 Mutation: Immuno Epidemiologic and Socio Epidemiologic Response. 5.COVID 19 Pandemic: Epidemic Curve Down Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS CoV2 Transmission & COVID 19 Fetal Survivability: Immuno epidemiologic Perspective. 7.SARS CoV2 (COVID 19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID 19 Pandemic Global Health Equity Transformation. 9.SARS CoV2 "Re emergence" as COVID 19 (2): Translational Public Health and Immuno epidemiologic Response. 10 .SARS CoV2 (COVID 19) Viral Dynamics Control. 11.Immune System Senescence in SARS CoV2 Transmission and COVID 19 Clinical Manifestations, Severity and Complications. 12.SARS CoV2 Exponential Spread and COVID 19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS CoV2 (COVID 19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS"¿ and SARS CoV2 (COVID 19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS CoV2 (COVID 19) Novel Variants (DELTA), Vaccine Cross effectiveness and Durability. 17.SARS CoV2 (COVID 19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities Blacks/African Americans (AA). 18.SARS CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health related Event in SARS CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS CoV2 (COVID 19) Vaccine Effectiveness and Durability in Immunogenic related Comorbidities (Multiple Myeloma). 21.SARS CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS CoV2 (COVID 19) Morbidity Implication in Chronic Disease (Type II Diabetes T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS CoV2 (COVID 19) Pandemic resurgence: Epigenomic Public Health Perspective. 25 .SARS CoV2 (COVID 19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26 .Black/African Americans (AA) and Disproportionate Burden of SARS COV 2 (COVID 19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS CoV2 and COVID 19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28 .Racial/Ethnic and Geo clustering Differentials in SARS CoV 2 (COVID 19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA
1.Immuno epidemiologic perspective in Pathogenic Microbes: Immune System Response & Integration. 2.Immuno epidemiologic perspective in Pathogenic Microbes: Epidemiologic Principles and Concepts. 3.SARS CoV2 (COVID 19): Pandemic and Public Health Emergency Response. 4.SARS CoV2 Mutation: Immuno Epidemiologic and Socio Epidemiologic Response. 5.COVID 19 Pandemic: Epidemic Curve Down Drifting and Case Fatality Mitigation. 6.Pregnancy Risk in SARS CoV2 Transmission & COVID 19 Fetal Survivability: Immuno epidemiologic Perspective. 7.SARS CoV2 (COVID 19) Risk Precipitation and Disproportionate Mortality in African American (AA)/Black Communities. 8.Social Injustice and Systemic Racism: Obstacles to COVID 19 Pandemic Global Health Equity Transformation. 9.SARS CoV2 "Re emergence" as COVID 19 (2): Translational Public Health and Immuno epidemiologic Response. 10 .SARS CoV2 (COVID 19) Viral Dynamics Control. 11.Immune System Senescence in SARS CoV2 Transmission and COVID 19 Clinical Manifestations, Severity and Complications. 12.SARS CoV2 Exponential Spread and COVID 19 Hospitalization, Case Fatality & Mortality: US Pandemic Mitigation and Stabilization Measures Regression. 13.SARS CoV2 (COVID 19) Synergistic Spread: Conjoint Effect of Personal Responsibility, Control/Preventive Measures and Vaccine Effectiveness. 14.SARS CoV2 Vaccine versus Vaccination: Immunologic Durability and Community Disproportionate Benefit in the United States & Globally. 15."COVIDMAS"¿ and SARS CoV2 (COVID 19) Pandemic Attenuation: Emerging new Strain (Antigenic Subtypes) and Subpopulations Obstacles to Vaccination. 16.SARS CoV2 (COVID 19) Novel Variants (DELTA), Vaccine Cross effectiveness and Durability. 17.SARS CoV2 (COVID 19) Disproportionate Burden: Hypertension and Mental Health among USA Racial/Ethnic Minorities Blacks/African Americans (AA). 18.SARS CoV2 Delta Variant (B.1.617.2) Transmissibility, Subpopulations Case positivity, Case Fatality and Mortality. 19.Natural Disaster (Hurricane) as Health related Event in SARS CoV2 Delta Variant Exponential Transmissibility and Mortality. 20.SARS CoV2 (COVID 19) Vaccine Effectiveness and Durability in Immunogenic related Comorbidities (Multiple Myeloma). 21.SARS CoV2 Omicron Variant: Transmissibility, Clinical Manifestations, Severity & Vaccine Effectiveness. 22.SARS CoV2 Omicron Variant Exponential Transmission & Mitigation Dynamics. 23.SARS CoV2 (COVID 19) Morbidity Implication in Chronic Disease (Type II Diabetes T2D) and Pancreatic Carcinoma. 24.Ukraine Invasion and Global SARS CoV2 (COVID 19) Pandemic resurgence: Epigenomic Public Health Perspective. 25 .SARS CoV2 (COVID 19) Global Pandemic: "Extreme Epidemiology" Response in Transmission and Case Fatality Stabilization, Mitigation & Control. 26 .Black/African Americans (AA) and Disproportionate Burden of SARS COV 2 (COVID 19) Mortality in the United States. 27.Epidemiologic Risk Modeling of Disproportionate Burden of SARS CoV2 and COVID 19 Mortality among Racial/Ethnic Minorities (Social Class) in Washington DC, USA. 28 .Racial/Ethnic and Geo clustering Differentials in SARS CoV 2 (COVID 19) Cumulative Incidence, Mortality and Temporal Trend in Delaware State, USA
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826